menu
    • menu
    [{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Leaps by Bayer"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"G-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Multiple Myeloma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Indapta Therapeutics

    Menu

    Indapta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $22.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Indapta Secures $22.5M to Advance Clinical Trials in Cancer and Autoimmune Care

                            Details : The financing will hep the company to advance the clinical development of IDP-023, which is being evaluated in the early-stage clinical trial studies for the treatment of multiple myeloma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $22.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indapta Treats First Patients with IDP-023 Allogeneic NK Cell Therapy for Cancer

                            Details : IDP-023 is a natural killer (NK) cell therapy which is currently being investigated in phase 1/2 clinical studies for the treatment of multiple myeloma and Non-Hodgkin’s lymphoma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 01, 2024

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Isatuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Indapta Announces Clinical Study Collaboration with Sanofi on Multiple Myeloma Program

                            Details : The collaboration will help Indapta to amend its ongoing phase 1 study of IDP-023, to add a cohort of IDP-023 in combination with Sarclisa for patients with relapsed/refractory multiple myeloma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : IDP-023,Isatuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Isatuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Indapta & Sanofi Collaborate on Clinical Study for Multiple Myeloma Program

                            Details : The grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : IDP-023,Isatuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CPRIT

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Indapta Therapeutics Awarded $4.5 Million by CPRIT for Allogenic Cell Therapy

                            Details : The grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 21, 2024

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CPRIT

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indapta Receives FDA Fast Track Designation for IDP-023 in Non-Hodgkin’s Lymphoma

                            Details : IDP-023 is an allogeneic G-NK cell therapy, which is being evaluated for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : IDP-023,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDP-023,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Leaps by Bayer

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell T...

                            Details : The financing will be used for the first-in-human phase 1 trial of DP-023, an Allogeneic Natural Killer (NK) Cell Therapy in patients with multiple myeloma and lymphoma.

                            Product Name : IDP-023

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : IDP-023,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Leaps by Bayer

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : G-NK Cell

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Seri...

                            Details : The company will use the proceeds of the financing to grow the team and continue to advance its universal, allogeneic NK cell platform toward an Investigational New Drug Application (IND) and clinical trials.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 02, 2022

                            Lead Product(s) : G-NK Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Multiple Myeloma Research Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical D...

                            Details : Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of monoclonal antibody therapy in multiple cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 28, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Multiple Myeloma Research Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Indapta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indapta Therapeutics Provides Updates on Its G-NK cell Therapy Program

                            Details : Company presented data from its G-NK cell therapy program in a poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in June.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 07, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth